Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents.
Year of Publication2022
Issuing InstitutionWHO
Recommendation
Status
Updated
Recommended in favor
Strong
Certainty of evidence
Very low
In children and adolescents between 3 months and 16 years of age with non-severe TB (without suspicion or evidence of multidrug- or rifampicin-resistant TB (MDR/RR-TB), a 4-month treatment regimen isoniazid –rifampicin–ethambutol optional–pyrazinamide (2HRZ(E)/2HR) should be used.